Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Homeopathic shot may shield cancer patients from chemo nerve pain

NCT ID NCT04715542

Prevention Sponsor: University of Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether a homeopathic remedy called Stibium metallicum praeparatum 6x can prevent or reduce nerve damage caused by the chemotherapy drug paclitaxel. The study will include 120 breast cancer patients who will receive either the remedy or a placebo injection three times a week during and for six weeks after chemotherapy. The goal is to see if this approach can reduce pain, tingling, and numbness, allowing patients to complete their cancer treatment without dose reductions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stibium metallicum praeparatum 6x (a homeopathic preparation of antimony)
What this could lead to
If it works, this could offer a way to prevent painful nerve damage from chemotherapy, helping patients complete their cancer treatment without dose reductions.
What could go wrong
This is a small, early-stage trial testing a homeopathic remedy, which has no proven biological mechanism. The effect may be no better than placebo, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 86 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age ≥ 18 * Early breast cancer, ovarian cancer or other gynecological cancer * Patients who are about to receive a treatment with paclitaxel for 12 or 18 weeks (weekly or three-weekly) as part of adjuvant or neo-adjuvant chemotherapy. * Ability to provide informed consent as documented by signature * Ability to read, write, and speak German Exclusion Criteria: * Patients with pre-existing neuropathy * Prior chemotherapy with taxanes or other neurotoxic agents * Concomitant medications that are known to cause neuropathy * Pregnancy or lactation * Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. * Patients with depression or epilepsy * Allergy to milk protein

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy induced peripheral neuropathy (CIPN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer chemotherapy-induced neuropathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy induced peripheral neuropathy (CIPN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.